Logo

GYRE

Gyre Therapeutics, Inc.

GYRE

Gyre Therapeutics, Inc. • NASDAQ
$7.75 ▼ -1.27% (-0.10)
Market Cap $704.05 M
52w High $14.42
52w Low $6.11
Dividend Yield 0%
P/E 193.75
Volume 19.74K
Outstanding Shares 90.85M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $30.564M ▲ $22.011M ▼ $3.61M ▲ 11.811% ▲ $0.27 ▲ $8.278M ▲
Q2-2025 $26.771M ▲ $23.449M ▲ $442K ▼ 1.651% ▼ $0.005 ▼ $2.813M ▲
Q1-2025 $22.058M ▼ $18.891M ▼ $2.698M ▲ 12.231% ▲ $0.03 ▲ $2.808M ▲
Q4-2024 $27.872M ▲ $26.098M ▲ $-99K ▼ -0.355% ▼ $-0.19 ▼ $1.134M ▼
Q3-2024 $25.488M $20.297M $1.124M 4.41% $0.058 $4.707M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $40.402M ▼ $159.384M ▲ $21.969M ▼ $101.92M ▲
Q2-2025 $54.365M ▲ $152.646M ▲ $23.203M ▼ $92.026M ▲
Q1-2025 $29.891M ▲ $129.79M ▲ $25.488M ▼ $68.123M ▲
Q4-2024 $26.671M ▲ $125.406M ▲ $27.004M ▲ $63.319M ▲
Q3-2024 $25.092M $125.24M $26.766M $63.179M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $5.936M ▲ $4.676M ▲ $-1.247M ▲ $365K ▼ $3.911M ▼ $3.993M ▲
Q2-2025 $1.576M ▼ $2.088M ▲ $-3.042M ▼ $22.351M ▲ $21.446M ▲ $1.809M ▲
Q1-2025 $3.734M ▲ $-129K ▲ $1.967M ▲ $1.344M ▲ $3.232M ▲ $-950K ▲
Q4-2024 $569K ▼ $-2.758M ▼ $-2.004M ▲ $964K ▲ $-4.053M ▼ $-3.503M ▼
Q3-2024 $1.124M $1.676M $-2.387M $374K $-231K $983K

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Product
Product
 $30.00M ▲$60.00M ▲$20.00M ▼$30.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Gyre is still very small in terms of revenue, but it has shown a clear shift from consistent losses toward roughly break-even, even edging into a small profit most recently. The cost base appears relatively contained, so modest revenue can move the company into or out of profit fairly easily. Overall, the pattern suggests an early commercial-stage biotech: thin revenue, improving profitability, but still highly sensitive to changes in sales or spending on research and development.

Balance Sheet

Balance Sheet The balance sheet is light, with a small asset base and limited cash, but it is notable that the company carries essentially no debt. Equity dipped into negative territory recently but has recovered, which indicates past strain followed by some recapitalization or improved results. Financial flexibility looks modest: the company is not weighed down by borrowings, but it does not have a large cushion of assets or cash either, so careful capital management remains important.

Cash Flow

Cash Flow Cash generation has improved, with operating cash flow moving from consistent outflows toward roughly break-even or slightly positive in the most recent period. Free cash flow is close to neutral, helped by minimal capital spending. This is encouraging for a biotech, but the absolute cash levels are small, meaning the company still operates with a tight margin for error and remains dependent on continued commercial performance or external funding over time.

Competitive Edge

Competitive Edge Gyre’s competitive strength comes from its specialization in anti-fibrotic therapies and its “China‑first” strategy. Through its Chinese subsidiary, it already markets a leading drug for lung fibrosis and has established nationwide commercial infrastructure and regulatory experience in China. This provides a base of know‑how, relationships, and revenue that many early-stage biotechs lack. However, it still competes in a crowded global biotechnology landscape, faces large multinational rivals in fibrosis, and is meaningfully exposed to regulatory and market dynamics in China.

Innovation and R&D

Innovation and R&D Innovation is the core of Gyre’s story. Its lead candidate, Hydronidone, targets liver fibrosis with evidence suggesting it might not only slow but potentially reverse disease progression, and it is already under regulatory review in China. The broader pipeline covers liver failure, chronic lung disease, and pulmonary hypertension, all areas with significant unmet medical need. The company also continues to develop new uses for its existing commercial drug in China. This focused but diversified R&D portfolio offers meaningful upside potential but also brings the usual biotech risks: trial setbacks, regulatory uncertainty, and long timelines.

Summary

Gyre looks like a transition-stage biotech: financially still small and delicate, but with improving profitability and cash flow supported by a real commercial footprint in China. Its strength lies in a clear therapeutic focus on fibrosis, a differentiated development strategy centered on China, and a pipeline that could materially change its scale if key drugs are approved and successfully launched. On the other hand, limited cash resources, dependence on a few core programs, and exposure to clinical and regulatory outcomes keep risk elevated. Future performance will hinge on how well it converts its scientific and strategic advantages into durable, diversified revenue while maintaining financial discipline.

NEWS

November 7, 2025 · 6:00 AM UTC

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

Read more

October 15, 2025 · 7:00 AM UTC

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

Read more

October 14, 2025 · 7:00 AM UTC

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

Read more

September 5, 2025 · 4:05 PM UTC

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read more